Gynecologic oncology reports · 2025
Development of immune radiotherapy with yttrium by targeting Frizzled homologue 10 (FZD10) in cervical cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Okuma Yuki, Ikeda Yuji, Kobayashi Osamu, Kamata Saki, Matsuda Erina, Nakajima Takahiro, Saito Keisuke, Tomita Naoko, Nakanishi Yoko, Harada Yosuke, Chung Suyoun, Park Jae-Hyun, Masuda Shinobu, Nakamura Yusuke, Kawana Kei
Аннотация
OBJECTIVE: Radioimmunotherapy (RIT) is a combination of the therapeutic properties of radioisotopes and specific antibodies used to eliminate tumors. 90Y-OTSA101 was developed by labeling Frizzled homologue 10 (FZD10) antibody with Yttrium-90 (90Y). Because cervical cancer exhibits good radiosensitivity, the present study aimed to assess for prevalence of FZD10 in cervical cancer tissue and investigate the potential of 90Y-OTSA101 treatment for cervical cancer.
METHODS: The expression of FZD10 was evaluated via immunohistochemistry using formalin-fixed paraffin blocks collected from 84 patients with cervical cancer who underwent surgery. Normal cervical from 10 patients, normal ovarian tissues from 10, uterine carcinomas from 10, and uterine sarcomas from 9 were used for comparison.Mice inoculated with the SiHa cell line, which is derived from cervical squamous cell carcinoma, were used to examine the effects of 90Y-OTSA101.
RESULTS: The evaluation results indicated that 70 (91 %) of the cervical cancer cases expressed FZD10 more frequently than 3 (30 %), 1 (10 %), 2 (20 %), and 0 (0 %) of the normal cervix, normal ovary, uterine carcinoma, and uterine sarcoma cases, respectively. The group treated with 3.7 MBq of 90Y-OTSA101 demonstrated greater antitumor effects, defined as tumor shrinkage or growth suppression, than the group treated with 1.85 MBq. No significant difference in body weight was observed between the groups during the observation period.
CONCLUSIONS: FZD10 may be an appropriate target and 90Y-OTSA101 may have potential for the treatment of cervical cancer.
METHODS: The expression of FZD10 was evaluated via immunohistochemistry using formalin-fixed paraffin blocks collected from 84 patients with cervical cancer who underwent surgery. Normal cervical from 10 patients, normal ovarian tissues from 10, uterine carcinomas from 10, and uterine sarcomas from 9 were used for comparison.Mice inoculated with the SiHa cell line, which is derived from cervical squamous cell carcinoma, were used to examine the effects of 90Y-OTSA101.
RESULTS: The evaluation results indicated that 70 (91 %) of the cervical cancer cases expressed FZD10 more frequently than 3 (30 %), 1 (10 %), 2 (20 %), and 0 (0 %) of the normal cervix, normal ovary, uterine carcinoma, and uterine sarcoma cases, respectively. The group treated with 3.7 MBq of 90Y-OTSA101 demonstrated greater antitumor effects, defined as tumor shrinkage or growth suppression, than the group treated with 1.85 MBq. No significant difference in body weight was observed between the groups during the observation period.
CONCLUSIONS: FZD10 may be an appropriate target and 90Y-OTSA101 may have potential for the treatment of cervical cancer.